Pharmacologic Weight-Loss Program

Malaysian Healthcare Providers Edition — Evidence-Based 2024/2025

Overview & Key Principles

-

Guideline Sources

Based on international clinical practice guidelines including WHO, American Endocrine Society, AACE/ACE Obesity Guidelines, Malaysian MOH Clinical Practice Guidelines, and peer-reviewed obesity pharmacotherapy literature (updated through 2024–2025).

Key Principles

  • Obesity is a chronic disease — requires long-term management, not a short-term fix
  • Pharmacotherapy must be combined with lifestyle intervention — medication alone is not recommended
  • GLP-1/GIP receptor agonists (semaglutide, tirzepatide) now produce the greatest weight reduction of any approved anti-obesity agent
  • BMI thresholds for Asians are lower — Malaysian MOH adopts BMI ≥27.5 as overweight and ≥32.5 as obese; pharmacotherapy thresholds align accordingly
  • Cardiovascular and metabolic benefits are a key driver for agent selection, especially semaglutide (SELECT trial: 20% CV event reduction)
  • Weight regain occurs on stopping medication — counsel patients that long-term or maintenance therapy is often necessary
  • Patient selection, comorbidity profiling and shared decision-making are essential before prescribing

Expected Weight Loss by Agent

Medication Category Average Weight Loss Mechanism
Tirzepatide (Mounjaro / Zepbound) AHighest 15–22% GLP-1 + GIP dual agonist
Semaglutide (Wegovy / Ozempic) AHighest 10–15% GLP-1 receptor agonist
Liraglutide (Saxenda) BModerate 5–8% GLP-1 receptor agonist (daily)
Phentermine-Topiramate (Qsymia) BModerate 8–10% Sympathomimetic + GABA modulation
Naltrexone-Bupropion (Contrave) BModerate 5–8% Opioid antagonist + dopamine reuptake inhibitor
Orlistat (Xenical / Alli) CLower 3–5% Pancreatic lipase inhibitor
Phentermine (short-term only) DShort-term 3–5% Sympathomimetic appetite suppressant

* Average weight loss at therapeutic/maximum tolerated dose combined with lifestyle intervention at 52–72 weeks. Individual results vary.

Patient Eligibility Criteria

-

BMI Thresholds for Pharmacotherapy

Standard international thresholds apply. For Asian/Malaysian patients, a lower clinical threshold is often appropriate given higher metabolic risk at lower BMI.

BMI CriterionInternationalMalaysian / Asian AdaptationIndication
Pharmacotherapy alone BMI ≥30 kg/m² BMI ≥27.5 kg/m² Obesity without comorbidity
Pharmacotherapy + comorbidity BMI ≥27 kg/m² BMI ≥23 kg/m² with significant comorbidity Overweight with metabolic complications

Qualifying Comorbidities

Type 2 Diabetes Hypertension Dyslipidaemia Obstructive Sleep Apnoea NAFLD / MASLD Cardiovascular Disease PCOS Prediabetes Osteoarthritis

Absolute Contraindications

Do NOT prescribe if:

  • Pregnancy or planning pregnancy (all agents)
  • Breastfeeding (all agents)
  • Personal or family history of medullary thyroid carcinoma (GLP-1 drugs)
  • MEN type 2 syndrome (GLP-1 drugs)
  • Severe uncontrolled hypertension
  • Uncontrolled psychiatric disease (Contrave, phentermine-topiramate)
  • Active suicidal ideation (Contrave, phentermine-topiramate)
  • History of pancreatitis — use GLP-1 agents with caution
  • Severe hepatic or renal impairment (agent-specific; see dosing)
  • Monoamine oxidase inhibitor (MAOI) use — contraindicated with Contrave

Additional Prescribing Considerations

  • Pharmacotherapy should not replace lifestyle intervention — it must accompany it
  • Realistic weight loss targets: 5% is clinically meaningful; 10–15% produces substantial metabolic benefit
  • Counsel patients about weight regain upon discontinuation — especially GLP-1 agents
  • Reassess at 12 weeks: if <5% weight loss at therapeutic dose, reconsider treatment
  • Screen for eating disorders before prescribing; active purging behaviour is a relative contraindication

Baseline Patient Assessment (Mandatory)

-

Complete the following before initiating any pharmacologic weight-loss therapy:

AssessmentParameterPurpose
Anthropometric
BMIHeight + Weight → BMI (kg/m²)Eligibility, baseline, monitoring
Waist circumference≥90 cm (M), ≥80 cm (F) = central obesity in AsiansCardiovascular risk stratification
Vital Signs
Blood pressureBoth arms; detect hypertensionContraindication screening; Contrave contraindicated in uncontrolled HTN
Heart rateResting pulseBaseline for sympathomimetic agents
Laboratory
Fasting glucose / HbA1cFBG & HbA1cDiabetes status, GLP-1 agent selection
Lipid profileTC, LDL, HDL, TGCardiovascular risk; orlistat benefit assessment
Liver function testsAST, ALT, ALP, bilirubinNAFLD/MASLD screen; contraindication check
Renal functioneGFR, creatinineDose adjustment for Contrave (avoid eGFR <30); GLP-1 caution
Thyroid functionTSH (± fT4)Rule out secondary obesity; GLP-1 thyroid safety
Uric acidSerum urateGout risk with weight cycling
Screening
Pregnancy testurine / serum hCGWomen of reproductive age — mandatory before GLP-1/any agent
Depression/anxiety screenPHQ-9, GAD-7Contrave and phentermine-topiramate — neuropsychiatric risk
Eating disorder screenClinical interviewBinge eating → Contrave may help; purging → caution
OSA screenSTOP-BANG questionnaireConsider sleep study if high risk

Malaysian-Specific Notes

  • Use Asian waist circumference cut-offs: ≥90 cm (men), ≥80 cm (women) for metabolic risk
  • HbA1c ≥5.7% (prediabetes range) strengthens indication for GLP-1 agents
  • Elevated ALT (>2× ULN) warrants hepatology input before prescribing
  • Ensure medication cost discussion — GLP-1 agents are currently not subsidised in Malaysia's public sector

Core Lifestyle Program (Mandatory)

-

Important

  • Medication alone is never recommended. Pharmacotherapy must always accompany structured lifestyle intervention.
  • Lifestyle therapy alone achieves 5–7% weight loss; combined with pharmacotherapy, outcomes are substantially better.
Diet Intervention
Caloric Deficit Core
500–750 kcal/day deficit from estimated total daily energy expenditure
Target: 0.5–0.75 kg/week weight loss
Higher deficit (1000 kcal) may be used short-term under supervision
Dietary Pattern Options
Low-carbohydrate diet (<130 g/day)
Effective short-term; reduces triglycerides and improves glycaemic control
Low-fat diet (<30% energy from fat)
Well-established; suits patients on orlistat
Mediterranean diet
Cardiovascular benefit; high adherence in Malaysian mixed population

Protein: Aim ≥1.2 g/kg ideal body weight/day to preserve lean mass during weight loss.

Physical Activity
Minimum Recommendation ACSM / WHO
150–300 minutes/week moderate-intensity aerobic exercise
e.g. brisk walking, cycling, swimming
For Weight Maintenance
≥300 minutes/week recommended
Resistance training 2× per week to preserve muscle mass

Note: Exercise alone produces modest weight loss (~2–3 kg) but significantly improves cardiovascular fitness, insulin sensitivity, and long-term maintenance.

Behavioural Therapy
  • Structured weight-management counselling (individual or group)
  • Self-monitoring: food diary, step counter, weight log
  • Goal-setting and problem-solving techniques
  • Cognitive behavioural therapy (CBT) for emotional eating
  • Motivational interviewing at each consultation
  • Address sleep hygiene — poor sleep increases ghrelin, worsens appetite control

Medication Classification

-
A Highest Efficacy — GLP-1 / GIP Agents (15–22% weight loss)
Tirzepatide Best Efficacy
GLP-1 + GIP dual receptor agonist
Mounjaro® (T2DM indication) Zepbound® (obesity indication)
Expected weight loss: 15–22% at max dose (SURMOUNT trials)
Indications: obesity ± T2DM. Superior glycaemic and weight outcomes vs semaglutide head-to-head (SURPASS-CVOT).
Semaglutide
GLP-1 receptor agonist (weekly injection)
Wegovy® (obesity) Ozempic® (T2DM)
Expected weight loss: 10–15% (STEP trials)
Wegovy 2.4 mg weekly = only formulation with obesity-specific approval. Ozempic 1 mg/0.5 mg — used off-label for weight in T2DM patients.
Cardiovascular benefit: SELECT trial — 20% reduction in major adverse cardiovascular events (MACE) in non-diabetic obese patients with established CVD.
B Moderate Efficacy (5–10% weight loss)
Phentermine-Topiramate
Sympathomimetic + GABA/glutamate modulator (oral)
Qsymia®
Expected weight loss: 8–10%
Avoid in pregnancy (topiramate is teratogenic — cleft palate). Mandatory pregnancy test before initiation.
Naltrexone-Bupropion
Opioid antagonist + dopamine/norepinephrine reuptake inhibitor (oral)
Contrave®
Expected weight loss: 5–8%
Particularly useful for emotional eating and food cravings — modulates dopamine reward pathway. Avoid with seizure history or MAOI use.
Avoid in severe renal (eGFR <30) or hepatic impairment. Reduces efficacy of opioid analgesics.
Liraglutide
GLP-1 receptor agonist (daily injection)
Saxenda® 3 mg
Expected weight loss: 5–8%
Daily injection vs weekly for semaglutide — adherence challenge. Suitable if weekly injection is declined or semaglutide unavailable.
C Lower Efficacy (3–5% weight loss)
Orlistat
Pancreatic lipase inhibitor (oral) — prevents fat absorption
Xenical® 120 mg Alli® 60 mg (OTC)
Expected weight loss: 3–5%
Most widely available in Malaysia; no systemic absorption. Useful for patients declining injections. GI side effects (oily stool) reduce acceptability — advise low-fat diet (<30% fat/day).
Also reduces LDL cholesterol and may lower T2DM progression.
D Short-Term Only (≤12 weeks)
Phentermine
Sympathomimetic appetite suppressant (oral)
Approved for maximum 12 weeks only (dependency risk; Schedule II/III controlled substance in many jurisdictions)
Typical dose: 15–37.5 mg daily. Expected weight loss: 3–5% over 12 weeks.
Avoid in cardiovascular disease, hypertension, hyperthyroidism, or concurrent MAOI use. Risk of tachycardia, anxiety, insomnia, and dependency.

Medication Selection Guide by Patient Profile

-

How to Use This Guide

Identify the patient's primary profile below. Multiple profiles may apply — prioritise the one with greatest comorbidity burden. All selections assume concurrent lifestyle therapy.

Profile 1 — Overweight (BMI 23–27.5) with Comorbidities, Budget-Conscious
Preferred Options First Line
Contrave (Naltrexone-Bupropion)
Oral, moderate cost, useful for cravings/emotional eating component
Orlistat (Xenical® / Alli®)
Lowest cost, OTC available, safe profile, no injection needed
Phentermine
Short-term only (≤12 weeks); useful kickstart if cardiovascularly safe

Avoid high-cost GLP-1 agents unless significant comorbidity or cardiovascular risk justifies cost.

Profile 2 — Obesity (BMI 27.5–32.5), No Major Metabolic Disease
Options
Contrave
Oral
Phentermine-Topiramate (Qsymia)
OralEnsure contraception
Saxenda (Liraglutide 3 mg)
Daily injection
Wegovy (Semaglutide 2.4 mg)
Weekly injectionPreferred if affordable
Profile 3 — Severe Obesity (BMI ≥32.5) or Target ≥10% Weight Loss
Preferred GLP-1 / GIP Agents
Tirzepatide (Mounjaro / Zepbound)
Highest efficacy available (15–22%); preferred for severe obesity
Semaglutide 2.4 mg (Wegovy)
10–15% weight loss; good alternative if tirzepatide unavailable

Discuss bariatric surgery referral if BMI ≥37.5 (or ≥32.5 with comorbidities) and pharmacotherapy is insufficient.

Profile 4 — Obesity + Type 2 Diabetes
First Choice Dual Benefit
Tirzepatide (Mounjaro)
Superior HbA1c reduction AND weight loss. Approved in Malaysia for T2DM.
Semaglutide (Ozempic 1 mg / Wegovy 2.4 mg)
Approved for T2DM (Ozempic) and obesity (Wegovy). Improves glucose control and cardiovascular risk.
Liraglutide 3 mg (Saxenda)
Alternative if weekly injections not feasible.

GLP-1 agents improve insulin resistance, HbA1c, and weight simultaneously — preferred over agents that only target weight.

Profile 5 — Obesity + Established Cardiovascular Disease
Preferred CV Outcome Data
Semaglutide 2.4 mg (Wegovy)
SELECT trial: 20% relative reduction in MACE in non-diabetic obese patients with established CVD. Only weight-loss drug with proven CV mortality benefit.
Tirzepatide (Mounjaro)
Emerging CV outcome data (SURMOUNT-MMO trial ongoing); likely similarly beneficial.

Avoid in Established CVD:

Phentermine, phentermine-topiramate, and Contrave — potential to increase heart rate and blood pressure.

Profile 6 — Emotional Eating / Food Cravings / Binge Eating
Preferred Dopamine Mechanism
Contrave (Naltrexone-Bupropion)
Mechanism: bupropion activates POMC neurons (appetite suppression); naltrexone blocks opioid-mediated reward of eating. Particularly effective for patients who describe food cravings and hedonic eating.

Screen for depression before prescribing — bupropion has antidepressant properties which may be beneficial or require monitoring.

Profile 7 — Patient Declines Injections (Oral Agents Only)
Oral Options Only
Contrave (Naltrexone-Bupropion)
5–8% weight loss; suitable for most adults
Orlistat 120 mg (Xenical)
3–5%; safe, no systemic effect, good for patients on multiple medications
Phentermine
Short-term only; ensure cardiovascular safety before prescribing

Note: Oral semaglutide (Rybelsus 7–14 mg) is approved for T2DM with modest weight benefit — not yet approved as obesity-specific treatment.

Dosing Protocols

-
Semaglutide (Wegovy®) — Weekly Subcutaneous Injection
Weeks 1–40.25 mg once weekly
Weeks 5–80.5 mg once weekly
Weeks 9–121.0 mg once weekly
Weeks 13–161.7 mg once weekly
Maintenance2.4 mg once weekly (target obesity dose)

If GI side effects are intolerable at any step, remain at the lower dose for an additional 4 weeks before escalating. Inject subcutaneously — abdomen, thigh, or upper arm. Rotate sites.

Tirzepatide (Mounjaro® / Zepbound®) — Weekly Subcutaneous Injection
Weeks 1–42.5 mg once weekly
Weeks 5–85 mg once weekly
Weeks 9–127.5 mg once weekly
Weeks 13–1610 mg once weekly
Weeks 17–2012.5 mg once weekly
Maintenance15 mg once weekly (maximum; use highest tolerated dose)

Increase dose every 4 weeks as tolerated. Dose reduction is acceptable if side effects limit escalation — clinical benefit is seen even at 5–10 mg.

Liraglutide (Saxenda®) — Daily Subcutaneous Injection
Week 10.6 mg once daily
Week 21.2 mg once daily
Week 31.8 mg once daily
Week 42.4 mg once daily
Maintenance3.0 mg once daily

If 3.0 mg is not tolerated, consider stopping — doses below 3.0 mg are not approved for obesity.

Naltrexone-Bupropion (Contrave®) — Oral Tablet (each tablet: 8 mg naltrexone + 90 mg bupropion)
Week 11 tablet in the morning
Week 21 tablet morning + 1 tablet evening
Week 32 tablets morning + 1 tablet evening
Week 4+2 tablets morning + 2 tablets evening (full dose)

Take with food to reduce nausea. Do not crush or chew (extended-release). Avoid high-fat meal with dose (increases bupropion absorption and seizure risk). Maximum: 32 mg naltrexone / 360 mg bupropion daily.

Reduce to 2 tablets once daily in mild-moderate renal impairment (eGFR 30–60). Contraindicated in eGFR <30.

Orlistat (Xenical® 120 mg) — Oral Capsule
Standard Dose120 mg three times daily with or just after each main meal containing fat

Skip dose if meal is missed or contains no fat. Supplement with fat-soluble vitamins (A, D, E, K) at bedtime — separated by ≥2 hours from dose. Advise dietary fat <30% of total calories to minimise GI side effects.

Phentermine — Oral (Short-Term Only)
Dose15–37.5 mg once daily — morning (to avoid insomnia)
DurationMaximum 12 weeks. Do not repeat courses without significant interval.

Monitor blood pressure and heart rate at every visit. Discontinue if heart rate consistently >100 bpm or BP poorly controlled.

Monitoring Protocol

-
VisitTimelineParameters to Assess
Initial Review 4 weeks after starting Tolerability, side effects, initial weight change, dose escalation readiness, blood pressure (phentermine/Contrave)
Efficacy Review 12 weeks at therapeutic dose Weight loss ≥5%? If not → consider stopping or switching. Check HbA1c (T2DM patients), BP, lipids
3-Month Review 3 months after initiation Weight, BMI, waist circumference, BP, glucose, lipids, LFTs (if orlistat), mental health screen
6-Month Review 6 months Full metabolic panel, dose optimisation, discuss long-term plan, assess adherence and lifestyle
Long-Term Every 6–12 months Weight maintenance, comorbidity reassessment, medication continuation decision, thyroid screen (annually for GLP-1 agents)

Stopping Rules — Discontinue If:

  • Weight loss <5% after 12 weeks at therapeutic dose
  • Intolerable side effects despite dose reduction
  • Symptoms of pancreatitis (severe abdominal pain, vomiting) — stop GLP-1 agent immediately
  • Confirmed or suspected pregnancy
  • New-onset cardiovascular contraindication (e.g. uncontrolled HTN on phentermine)
  • Suicidal ideation or serious neuropsychiatric event (Contrave, phentermine-topiramate)

Programme Exit & Maintenance Options

  • Maintenance dose GLP-1: Many patients require ongoing therapy to prevent weight regain — particularly semaglutide and tirzepatide. Discuss this at initiation.
  • Lifestyle only: If ≥10% weight loss achieved and maintained, structured lifestyle programme alone may suffice for motivated patients.
  • Switch to lower-cost oral agent: If budget is a concern after achieving target weight with injectable, consider switching to orlistat or Contrave for maintenance.
  • Bariatric surgery referral: If pharmacotherapy insufficient (BMI ≥37.5, or ≥32.5 with comorbidities) — refer to bariatric surgeon.

Safety Profile & Side Effects

-
AgentCommon Side EffectsSerious / RareMonitoring
GLP-1 / GIP agents
(Semaglutide, Tirzepatide, Liraglutide)		 Nausea (very common), vomiting, diarrhoea, constipation, injection site reactions, reduced appetite Pancreatitis (rare), gallstones / cholecystitis, tachycardia, medullary thyroid tumours (animal data only), hypoglycaemia (if combined with sulphonylurea/insulin) Amylase/lipase if abdominal pain; gallbladder ultrasound if symptoms; thyroid exam
Contrave
(Naltrexone-Bupropion)		 Nausea, constipation, headache, dizziness, insomnia, dry mouth Seizure risk (dose-dependent), suicidal ideation (FDA black box — monitor in first months), elevated BP, serotonin syndrome (rare) BP and HR each visit; PHQ-9 at baseline and 1 month; avoid in seizure disorder
Phentermine-Topiramate Dry mouth, paraesthesia, constipation, insomnia, dysgeusia, cognitive effects (topiramate) Teratogenicity (cleft palate — topiramate), metabolic acidosis, kidney stones, angle-closure glaucoma, suicidal ideation Pregnancy test before and monthly; serum bicarbonate periodically; renal function
Orlistat Oily spotting, faecal urgency, oily or fatty stools, flatus with discharge, frequent bowel movements Rare: severe hepatic injury (post-marketing, mechanism unclear); oxalate nephropathy with high oxalate diet LFTs if symptoms; advise adequate hydration; fat-soluble vitamin supplementation
Phentermine Tachycardia, palpitations, increased BP, anxiety, insomnia, dry mouth, euphoria Dependency / abuse potential; severe hypertension; pulmonary arterial hypertension (rare) BP and HR at every visit; strictly ≤12 weeks; do not combine with other sympathomimetics

Managing GLP-1 Nausea (Most Common Reason for Discontinuation)

  • Inject at the same time each week — evening injections may reduce peak nausea during the day
  • Eat smaller meals, slowly; avoid high-fat or high-sugar meals immediately after injection
  • Avoid lying down immediately after eating
  • Stay at lower dose for 4–8 extra weeks if nausea persists before escalating
  • Ondansetron or metoclopramide may be used short-term for severe nausea
  • Reassure patients: nausea typically improves after weeks 4–8 and often resolves

Clinic Weight-Loss Program Structure

-
StepActivityWhoTiming
1Initial obesity consultation — history, BMI, waist, comorbidities, expectationsDoctorVisit 1
2Baseline metabolic blood screening (FBG, HbA1c, lipids, LFTs, renal, TSH, uric acid)Doctor / NurseVisit 1
3Pregnancy test (women of reproductive age) + depression / eating disorder screenNurse / DoctorVisit 1
4Review blood results, medication selection & shared decision-making, informed consentDoctorVisit 2
5Personalised diet plan referral (dietitian) or structured clinic diet counsellingDietitian / DoctorVisit 2
6Exercise prescription — type, frequency, target HR, written planDoctor / NurseVisit 2
7Injection technique training (if GLP-1 agent prescribed), sharps disposal educationNurseVisit 2
84-week tolerability review — side effects, dose escalation decisionDoctor / NurseWeek 4
912-week efficacy check — weight, BP, glucose. Stopping rule assessment if <5% lossDoctorWeek 12
10Monthly monitoring — weight, waist, BP, wellbeing, adherence, lifestyle reviewNurse / DoctorMonthly
116-month full metabolic panel review + medication adjustment or continuationDoctorMonth 6
12Long-term maintenance planning — dose, lifestyle, bariatric referral if indicatedDoctorOngoing

Malaysian Context Notes

  • GLP-1 agents (Ozempic, Mounjaro) are available in private pharmacies/clinics; not currently on MOH subsidised drug formulary for obesity
  • Orlistat 120 mg (Xenical) is available with prescription; 60 mg (Alli) is OTC
  • Contrave and Qsymia availability varies — confirm with local pharmaceutical suppliers
  • Document informed consent for off-label use if prescribing Ozempic for weight loss in non-diabetic patients
  • Advise patients on medication shortages — semaglutide supply has been intermittent globally
  • Sharps disposal: advise patients to use dedicated sharps bins; arrange disposal per local waste management guidelines

Documentation Reminders

  • Record baseline BMI, waist circumference, BP, and metabolic results in patient notes
  • Document informed consent — especially for GLP-1 agents regarding GI risk, thyroid risk, and injection training
  • Record stopping rule assessment at 12 weeks explicitly
  • Note contraception status for women of reproductive age on phentermine-topiramate
  • Flag pregnancy test result before each prescription renewal for teratogenic agents

⚙️ Obesity Medication Profiling Tool

-
Evidence-Based Medication Selection for This Patient
Fill in the patient profile → get ranked medication recommendations with contraindications, drug interactions, dosing schedules, and a printable patient counselling sheet.
Based on: EASO 2025 · ACC 2025 · WHO 2025 · SURMOUNT · SELECT · STEP-HFpEF · SUMMIT · SYNERGY-NASH
👤 Patient Details
*Recommended if CKD/T2DM/HTN
🏥 Comorbidities & Medical History
Metabolic & Cardiovascular
Kidney, Liver & GI
Neurological & Psychiatric
Endocrine & Other
💊 Current Medications
Diabetes Medications
Psychiatric / Neurological
Cardiovascular / Other
⚙️ Patient Preferences
Route Preference
Primary Goal
Cost Sensitivity

🔬 Emerging Therapies & Weight Loss Calculator

-
⚖️ Weight Loss & Regain Calculator
Enter patient weight and select medication → see expected weight loss in kg, timeline, and weight regain trajectory after stopping
Important: Weight loss estimates are based on clinical trial averages at maximum tolerated dose combined with lifestyle intervention. Real-world results typically 30–40% lower than trial data. Individual results vary significantly. These figures are for patient counselling and expectation-setting only.
⚠️ Weight Regain After Stopping Medication
Published data shows most patients regain significant weight after stopping anti-obesity medications. This is critical information for shared decision-making and long-term planning.
Drug Weight Regain at 1 Year After Stopping Key Trial Clinical Implication
Tirzepatide ~50% of lost weight regained within 1 year SURMOUNT-4 (2023) Long-term therapy likely needed for weight maintenance
Semaglutide 2.4mg ~67% of lost weight regained within 1 year STEP-4 withdrawal (2021) Most patients require ongoing treatment; discuss at initiation
Liraglutide ~50–60% of lost weight regained within 1 year SCALE Maintenance (2016) Similar pattern to semaglutide — chronic disease model applies
Naltrexone-Bupropion ~30–50% of lost weight regained within 1 year COR extension studies Less dramatic but still significant regain
Orlistat ~30–40% of lost weight regained within 1 year XENDOS follow-up Lower regain but also lower initial weight loss
Phentermine (short-term) Most weight regained within 6 months Multiple observational studies Short-term use only — must have exit strategy / transition plan
Key message for patients: Obesity is a chronic disease. Stopping medication is like stopping antihypertensives — the underlying condition remains. Discuss long-term continuation, maintenance dosing, or transition strategies at the time of prescribing — not as an afterthought.
🧬 Emerging Therapies — Pipeline (Not Yet Approved)
The following agents are in Phase 2/3 trials. Information is for educational awareness only. None are currently approved for clinical use.
Retatrutide
GLP-1 + GIP + Glucagon Triple Agonist
Phase 3 Trials Ongoing
Phase 2 trial: up to 24.2% weight loss at 48 weeks — the highest ever recorded for any pharmacological agent. Triple mechanism: GLP-1 (appetite), GIP (metabolism), Glucagon (energy expenditure) act simultaneously.
💡 Significance: Could surpass tirzepatide as most effective non-surgical weight loss option
ETA: FDA submission estimated 2025–2026. Not yet approved anywhere.
CagriSema
Cagrilintide + Semaglutide Combination
Phase 3 — REDEFINE Trials
REDEFINE-1 trial: ~22–25% weight loss at 68 weeks. Cagrilintide is an amylin analogue (targets satiety centre differently to GLP-1); combined with semaglutide gives complementary dual mechanism. May carry semaglutide's proven CV benefit.
💡 Significance: Offers GLP-1 CV benefit + greater weight loss than semaglutide alone
ETA: Phase 3 results 2025. Regulatory submission likely 2026.
Orforglipron
Oral GLP-1 Receptor Agonist (Non-peptide Small Molecule)
Phase 3 Trials
Phase 2: ~14.7% weight loss at 36 weeks — comparable to injectable semaglutide. Key advantage: oral once-daily tablet — no injection, no refrigeration required, dramatically lower manufacturing cost. Non-peptide structure means stable at room temperature.
💡 Game-changer: Injectable GLP-1 efficacy in a daily tablet — could massively expand access globally including Malaysia
ETA: Phase 3 ongoing. Potential approval 2026–2027.
Mazdutide
GLP-1 + Glucagon Dual Agonist
Phase 3 (China/Global)
Phase 2/3 data from Chinese trials: significant weight loss and metabolic improvement. Different from tirzepatide — uses glucagon (not GIP) as the second target. Glucagon component increases energy expenditure via brown fat activation. May have particular advantages for MASLD due to glucagon's hepatic effects.
💡 Significance: Alternative dual-agonist; notable MASLD potential; lower cost expected vs Mounjaro
ETA: Phase 3 ongoing. Approval timeline for Malaysia/global uncertain.
📊 Emerging vs Current — Weight Loss Comparison
Agent Type Weight Loss Status Route
RetatrutideGLP-1+GIP+GCG Triple~24%Phase 3Weekly injection
CagriSemaAmylin + GLP-1~22–25%Phase 3Weekly injection
Tirzepatide ✓ APPROVEDGLP-1+GIP Dual15–21%ApprovedWeekly injection
Semaglutide 2.4mg ✓ APPROVEDGLP-113–15%ApprovedWeekly injection
OrforglipronOral GLP-1~15%Phase 3Oral tablet 💊
MazdutideGLP-1+GCG Dual~15–20%Phase 3Weekly injection
⚠️ WARNING: Counterfeit & Unregulated GLP-1 Products
  • !Counterfeit Ozempic (semaglutide) has been confirmed by FDA and reported globally including in Asia
  • !Unregulated compounded semaglutide and tirzepatide widely sold online and via unlicensed channels in Malaysia
  • !Counterfeit products may contain wrong doses, wrong ingredients, no active ingredient, or harmful contaminants
  • !WHO December 2025 global alert on falsified GLP-1 products — patient safety risk
  • !ALWAYS obtain from licensed pharmacy with valid prescription. Semaglutide & tirzepatide require refrigeration (2–8°C) — if arrived unrefrigerated, do not use
  • !Report suspected counterfeits: Malaysia NPRA: 1-800-88-1111